TY - JOUR
T1 - Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks
AU - Ji Nam, Eun
AU - Lee, Maria
AU - Yim, Gawon
AU - Hoon Kim, Jae
AU - Kim, Sunghoon
AU - Wun Kim, Sang
AU - Wook Kim, Jae
AU - Kim, Young Tae
PY - 2013/6
Y1 - 2013/6
N2 - Purpose. The aim of this study was to assess the activity and toxicity of primary carboplatin-based chemoradiotherapy (CarboRT) and to compare CarboRT with cisplatinbased chemoradiotherapy (CisRT) in patients with locally advanced cervical cancer and poor general condition. Patients and Methods. Fifty-one locally advanced cervical cancer patients with morbidity risks were prospectively enrolled between January 2007 and April 2010. Eligible patients received weekly intravenous CarboRT with carboplatin 100 mg/m2, and a comparison was made with a historical patient group that received weekly CisRT with cisplatin 40 mg/m2. Results. Median follow-up was 36 months(range:4-66 months) in the CarboRT group and 53 months (range: 4-121 months) in the CisRT group. Compared with the historical CisRT group, the CarboRT group showed no statistically significant differences in recurrence (hazard ratio [HR], 1.21; 95% confidence interval [CI], 0.52-2.81) and survival (HR, 1.80; 95% CI, 0.49-6.54).The mean numbers of received cycles of CarboRT and CisRT were 7.5 ± 1.4 and 6.0 ± 1.8, respectively (p<.001). The rates of grade 3-4 toxicity were similar in the two groups. Conclusions. CarboRT was better tolerated than CisRT without compromising tumor response and survival in patients with locally advanced cervical cancer and poor general condition.
AB - Purpose. The aim of this study was to assess the activity and toxicity of primary carboplatin-based chemoradiotherapy (CarboRT) and to compare CarboRT with cisplatinbased chemoradiotherapy (CisRT) in patients with locally advanced cervical cancer and poor general condition. Patients and Methods. Fifty-one locally advanced cervical cancer patients with morbidity risks were prospectively enrolled between January 2007 and April 2010. Eligible patients received weekly intravenous CarboRT with carboplatin 100 mg/m2, and a comparison was made with a historical patient group that received weekly CisRT with cisplatin 40 mg/m2. Results. Median follow-up was 36 months(range:4-66 months) in the CarboRT group and 53 months (range: 4-121 months) in the CisRT group. Compared with the historical CisRT group, the CarboRT group showed no statistically significant differences in recurrence (hazard ratio [HR], 1.21; 95% confidence interval [CI], 0.52-2.81) and survival (HR, 1.80; 95% CI, 0.49-6.54).The mean numbers of received cycles of CarboRT and CisRT were 7.5 ± 1.4 and 6.0 ± 1.8, respectively (p<.001). The rates of grade 3-4 toxicity were similar in the two groups. Conclusions. CarboRT was better tolerated than CisRT without compromising tumor response and survival in patients with locally advanced cervical cancer and poor general condition.
UR - http://www.scopus.com/inward/record.url?scp=84880664901&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880664901&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2012-0455
DO - 10.1634/theoncologist.2012-0455
M3 - Article
C2 - 23821328
AN - SCOPUS:84880664901
VL - 18
SP - 843
EP - 849
JO - Oncologist
JF - Oncologist
SN - 1083-7159
IS - 7
ER -